uploads/2017/01/cl-anr-2.png

How Do Analysts Rate Colgate-Palmolive and Its Peers?

By

Updated

Analysts’ ratings

Of the 20 analysts covering Colgate-Palmolive (CL) stock, three of them, or 15.0%, have rated the stock a “buy” as of January 27, 2017. The stock is rated “hold” by 85.0% of analysts.

Analysts have set the stock’s 12-month price target at $71.73 per share with an upside potential of 11.0%. Colgate-Palmolive is a leading consumer products company with some globally recognized brands in its portfolio.

Consensus rating

Colgate-Palmolive has reported a fall in sales growth for nine consecutive quarters. However, the company has been able to post growth in its adjusted EPS (earnings per share) for two consecutive quarters, helped by the successful implementation of its cost-savings program.

However, the company is cautious when it comes to its fiscal 2017 guidance. Uncertainty in global markets and foreign exchange fluctuations are key concerns for the company.

Colgate-Palmolive makes up 2.9% of the Vanguard Consumer Staples ETF (VDC).

Comparison with peers

Of the 21 analysts covering Procter & Gamble (PG) stock, ten of them, or 48.0%, have rated the stock a “buy” as of January 27, 2017. The stock is rated a “hold” by 43.0% of analysts and a “sell” by 9.0%. Analysts have set the stock’s 12-month price target at $90.53 per share with an upside potential of 4.0%.

Of the 15 analysts covering Clorox (CLX) stock, 13.0% have rated it a “buy,” 74.0% rated it a “hold,” and 13.0% rated it a “sell.” The 12-month average stock price target for Clorox is $121.55 per share, reflecting an upside potential of 1.0%.

For Kimberly-Clark (KMB), 14.0% of the 14 analysts covering the stock rated it a “buy,” 72.0% rated it a “hold,” and 14.0% rated it a “sell.” Analysts have set the average 12-month stock price target at $124.67 per share with an upside potential of 3.0%.

We’ll look at Colgate-Palmolive’s valuation in the next and final part of this series.

More From Market Realist